OXB Oxford Biomedica Plc

Subscription of shares by Institut Mérieux

Oxford, UK - 18 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that an application has been made to the Financial Conduct Authority and the London Stock Exchange for the admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for the listing of 5,201,107 new ordinary shares of 50 pence each ("Admission"), representing 4.9% of the Company's enlarged issued share capital following the issue of such new ordinary shares. The new ordinary shares will be issued on a non pre-emptive basis utilising the authority granted at the Group's 2023 AGM.

The Admission is in respect of a EUR 20 million investment (£16.9 million) by TSGH SAS, a subsidiary of Institut Mérieux SA ("Institut Mérieux") which has been made at a share price of 325p per ordinary share, being the 30-day VWAP to closing on 17 June 2024. As previously communicated, this investment follows Oxford Biomedica's acquisition of ABL Europe SAS, (since renamed Oxford Biomedica (France) SAS ("OXB France")) from Institut Mérieux, which was completed on 29 January 2024. The announcement can be found here. The acquisition of OXB France has enhanced OXB's bioprocessing and manufacturing footprint in the EU, strengthening the Group's multi-vector, multi-site model and adding specialised expertise in the development and manufacturing of solutions for biotech and biopharma companies.

The Admission is expected to occur on 19 June 2024. Following Admission and following the previously announced transaction and purchases in the open market, Institut Mérieux will hold a 10.9% stake in Oxford Biomedica, making it a major, long-term shareholder and further underpinning conviction in OXB's strategy.

-Ends-

ABOUT OXFORD BIOMEDICA

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.  

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.